PREFACE

Quality Enhancement Research Initiative’s (QUERI) Evidence-based Synthesis Program (ESP) was established to provide timely and accurate syntheses of targeted healthcare topics of particular importance to Veterans Affairs (VA) managers and policymakers, as they work to improve the health and healthcare of Veterans. The ESP disseminates these reports throughout VA.

QUERI provides funding for four ESP Centers and each Center has an active VA affiliation. The ESP Centers generate evidence syntheses on important clinical practice topics, and these reports help to:

- develop clinical policies informed by evidence
- guide the implementation of effective services to improve patient outcomes and to support VA clinical practice guidelines and performance measures, and
- set the direction for future research to address gaps in clinical knowledge

In 2009, the ESP Coordinating Center was created to expand the capacity of QUERI Central Office and the four ESP sites by developing and maintaining program processes. In addition, the Center established a Steering Committee comprised of QUERI field-based investigators, VA Patient Care Services, Office of Quality and Performance, and Veterans Integrated Service Networks (VISN) Clinical Management Officers. The Steering Committee provides program oversight, guides strategic planning, coordinates dissemination activities, and develops collaborations with VA leadership to identify new ESP topics of importance to Veterans and the VA healthcare system.

Comments on this evidence report are welcome and can be sent to Nicole Floyd, ESP Coordinating Center Program Manager, at nicole.floyd@va.gov.

TABLE OF CONTENTS

EXECUTIVE SUMMARY
Background ................................................................................................................................................1
Methods ..................................................................................................................................................1
Peer Review ..........................................................................................................................................2
Results ..................................................................................................................................................2
Abbreviations Table ...............................................................................................................................3

INTRODUCTION .................................................................................................................................4

METHODS
Adapting Previously Developed HCV Model to VA .................................................................................5
Preliminary Analyses of VA Administrative Data ......................................................................................8
Peer Review ..........................................................................................................................................12

RESULTS
Results Used to Inform the Model ..........................................................................................................13
Key Question #1. What are the current usage patterns of directly acting antivirals and of IL-28B patient genotyping in the VA health system? And how do these patterns differ by VISN? ......................21
Key Question #2. What will be the health impacts of using either of two available directly acting antivirals combined with pegylated interferon and ribavirin (triple therapy)? ..........................................................23
Key Question #3. How will the magnitudes of the health impacts measured in Key Question #2 change if IL-28B patient genotyping is used to offer triple therapy to those less likely to benefit from two-drug pegylated interferon + ribavirin? .................................................................24
Key Question #4. What will be the cost and resource use patterns when using either triple therapy or IL-28B-guided triple therapy? ................................................................................................................25

SUMMARY AND DISCUSSION
Summary of Evidence by Key Question ..................................................................................................26
Limitations ...............................................................................................................................................27
Recommendations for Future Research ..................................................................................................28
Conclusions ............................................................................................................................................28

REFERENCES ........................................................................................................................................29

APPENDIX A. PEER REVIEW COMMENTS/AUTHOR RESPONSES ..................................................32

TABLES
Table 1. Number of Sources Identified for Each Model Attribute/Area .....................................................13
Table 2. Demographic Characteristics Assumed for VA HCV GT1 Population .........................................14
Table 3. Transplantation for Advanced Liver Disease Related to HCV ....................................................14
Table 4. Treatment Parameters Estimates for the VA HCV GT1 Population ...........................................16
Table 5. VA-specific Cost Inputs ............................................................................................................17
Table 6. Treatment Eligibility and Uptake over 5 Years (number of Veterans) .........................................21
Table 7. Annual Effect of Universal Triple Therapy on Health Outcomes over 5 Years .................. 24
Table 8. Annual Effect of IL-28 Guided Triple Therapy on Health Outcomes over 5 Years .......... 24
Table 9. Average Annual Net Increase in Cost by Treatment Strategy and Uptake Rate over the 5 Years of the Analysis Relative to Standard Therapy .................................................. 25

FIGURES

Figure 1. Decision Model (Panel A) and HCV Natural History Model (Panel B) ......................... 6
Figure 2. Cumulative Proportion of Treatment-eligible, Chronic HCV Individuals Taking Up Therapy ................................................................................................................. 20
Figure 3. Uptake of DAA Therapies by VISN (x-axis denotes VISN number) .......................... 21
Figure 4. Use of IL-28B Testing and DAAs by VISN ................................................................. 22
Figure 5. The Days on Treatment for Each DAA Appear Reasonably in Line with Its Therapeutic Protocols ........................................................................................................ 23
EVIDENCE REPORT

INTRODUCTION

There is great potential to improve health outcomes for Veterans and other patients with chronic genotype 1 (GT1) Hepatitis C (HCV) infections through the use of newly-available directly acting antiviral (DAA) medications and patient genotyping (IL-28B). Chronic GT1 HCV infections have been historically difficult to treat with low cure rates on standard two drug therapy (Pegylated Interferon + Ribavirin), high rates of side-effects and treatment discontinuation, and low rates of uptake. Recently, FDA approved two DAAs (boceprevir and telaprevir). Used in combination with standard two drug therapy as triple therapy, these DAAs show higher rates of sustained viral response, though they are also more costly and have more severe side-effect profiles. IL-28B genotyping can help to identify patients least likely to respond to standard therapy and hence who stand to benefit the most from triple therapy and for whom, therefore, the increased risks of side-effects may be most justified.

To achieve the potential health benefits from DAAs and IL-28B genotyping while acknowledging very real budgetary and resource constraints, proactive planning supported by appropriate analyses is needed. VA added boceprevir to its formulary approximately a year ago, allows the use of telaprevir off formulary for a number of reasons, and has the capability to use IL-28B patient genotyping as well. Responding to a request for guidance submitted to the VA Evidence-based Synthesis Program (ESP), we undertook a set of preliminary studies aimed at providing rapid, timely estimates of cost, resource and health impacts of using DAAs and/or IL-28B genotyping within VA over a 5 year time horizon.

Specifically, we addressed four related questions:

- **Key Question #1**: What are the current usage patterns of directly acting antivirals and of IL-28B patient genotyping in the VA health system? And how do these patterns differ by VISN?

- **Key Question #2**: What will be the health impacts of using either of two available directly acting antivirals combined with pegylated interferon and ribavirin (triple therapy)?

- **Key Question #3**: How will the magnitudes of the health impacts measured in Question #2 change if IL-28B patient genotyping is used to offer triple therapy to those less likely to benefit from two-drug pegylated interferon + ribavirin?

- **Key Question #4**: What will be the cost and resource use patterns when using either triple therapy or IL-28B-guided triple therapy?

We answered these questions over a 5 year time horizon, comparing health outcomes and costs of standard two-drug treatment to adoption of these new technologies. Importantly, these results are appropriate for short-term budgeting and planning considerations but they should not be used for formal cost-effectiveness analyses as they do not represent the full costs and benefits experienced over a life time.
METHODS

We undertook three main activities to answer these questions. First, we performed an observational analysis of VA data to evaluate the uptake, use, and costs of therapies for HCV. This characterized the current state of DAA and IL-28B testing within VA in roughly the first year since adoption. Observational analysis was also used to estimate the cost of care for patients with liver disease.

Second, we adapted our previously-developed HCV computer model to more closely reflect VA patient populations with chronic GT1 HCV infections and patterns of HCV care in VA. In order to adapt this model, we performed a rapid literature review for chronic HCV-related studies from 2000-2012 that focused on VA populations. This review included peer-reviewed literature and for other reports. We performed preliminary analyses of VA administrative data to examine the usage patterns of DAAs and IL-28B in VA in the past year and the cost of care of patients with HCV. We used this information in the computer model so that it would reflect the VA patient population and care practices.

Third, using the adapted model, we then performed model-based projections of health outcomes and costs of alternative HCV treatment strategies.

ADAPTING PREVIOUSLY DEVELOPED HCV MODEL TO VA

Brief description of the HCV computer model

The computer simulation model of HCV we use here has been described in detail previously. For convenience, we describe it here briefly. The model has two main parts:

1. **Decision model** that incorporates alternative treatment strategies for chronic GT1 HCV and potentially uses IL-28B genotyping to select the most appropriate treatment for a patient based on the IL-28B genotype results (Figure 1 Panel A).

2. **HCV natural history** model that projects the course of future health prior to initiating, during, and after treatment and also tracks clinical events, resource utilization, costs, morbidities, and mortality (Figure 1 Panel B).
The model is stratified by a set of cohort characteristics including age, sex, race, IL-28B genotype, and stage of liver fibrosis (Metavir score F0-F4). While IL-28B genotypes include CC, CT, and TT, the similarity of response to therapy for CT and TT and the relatively limited amount of data on these types, especially when further stratified by race, led us to combine them into non-CC.

Three main strategies are included in the model. The first is standard therapy, the continued use of 48 weeks of Pegylated Interferon + Ribavirin for all patients regardless of IL-28B genotype (i.e., without genotyping them). The second strategy is universal triple therapy, the use of DAAs in combination triple therapy for all patients regardless of IL-28B genotype (i.e., without genotyping them). The third strategy considered is IL-28B guided triple therapy. In the strategy, patients are first tested for the IL-28B genotype. Patients with CC type are most likely to respond to standard therapy and are directed to the treatment. Those with non-CC types are provided with triple therapy. All strategies use specific response guided protocols (not shown). Models for all strategies include risks, costs, and quality-of-life reductions due to side-effects as well as the possibility of non-adherence and discontinuation above and beyond response guided protocols.

The HCV natural history model tracks individuals at 4 week intervals. During each interval, people have the chance of transition along the solid black arrows which represent progression through various states of liver fibrosis, advanced liver disease including decompensated cirrhosis, and death from liver-related complications.
hepatocellular carcinoma, and liver transplantation. At all times, people have an age, sex, and race specific risk of death with elevated risks for advanced liver disease. Successful treatment that leads to SVR and cure allows individuals to transition along the dashed arrows to “recovered” states that are stratified by fibrosis severity. In recovered states, individuals have lower mortality risks and lower ongoing medical care costs than in the corresponding states prior to recovery.

The model considers chronic GT1 HCV individuals who are HCV treatment naïve who do not have a co-occurring HIV infection.

**Literature Review of Veteran-related Chronic HCV-related Studies from 2000-2012**

We conducted a rapid evaluation of references for information on chronic HCV infection in U.S. Veterans. Because of the limited time available, we did not undertake the formal methods of a systematic literature review. We searched PubMed for published studies from 2000-2012 on topics that included both “chronic HCV” and “veterans.” Identified abstracts were reviewed and full text of articles obtained. We further reviewed these articles’ bibliographies for other important sources that the search may have missed. Additionally, we performed web searches and VA-specific website searches to locate VA reports and other public, non-journal-published data relevant to these topics. We then extracted information from these sources. When we combined information from the studies and sources described above, we gave precedence to recent studies, large studies, representative studies, and high-quality studies. We did not assess articles formally for quality and attempted to be as inclusive as possible. Articles were excluded that did not report provide sufficient detail on a needed parameter.

Mortality in Veterans regardless of HCV has been modeled actuarially as reflected in the VA’s VetPop 2007 model (www.va.gov/VETDATA/Demographics/Demographics.asp).

Additional information on mortality relating to HCV and liver disease is reported in a number of studies. 23, 29, 31 We combined this information on VA-specific age and sex-stratified mortality rates, using NHANES (National Health and Nutrition Examination Survey) III linked estimates of hazard rate ratios for mortality due to HCV by race/ethnicity to reflect the background mortality patterns of individuals within VA with chronic HCV infections.

**Preparing the Model for Performing Preliminary Projections on Cost and Outcomes for the VA’s Chronic HCV GT1 Population**

The preliminary resource analysis considered a representative cohort of chronic HCV GT1 infected individuals in VA. In the analysis, scenarios are considered that use DAAs (Key Question 2, Key Question 4) alone or with IL-28B patient genotyping (Key Question 3, Key Question 4) as an alternative to standard two drug therapy and in which treatment uptake may differ from the past. Each scenario examines the costs of delivering such treatments over a 5 year window of time as well as the health benefits within this 5 year window.

Importantly, costs and benefits are reported for these 5 particular years only. As they do not include subsequent costs or benefits beyond these 5 years, this analysis CANNOT be used to assess the cost-effectiveness of these treatment strategies. Cost-effectiveness analysis employs a lifetime time horizon, considering all costs and benefits over the patients’ lifetimes.
Representative Cohort of Chronic HCV GT1 Infected Individuals in VA
We defined a representative cohort of chronic HCV GT1 infected individuals in VA based on published studies of VA HCV populations and other VA-specific documents and data that are described in the results.

Treatment-eligible Patient Population and Uptake Scenarios
To provide estimates of total costs due to DAAs and IL-28B genotyping, it is necessary to determine the size of the treatment-eligible patient population and likely patterns of treatment uptake. We then combined the update scenarios with the treatment-eligible population for analyses.

PRELIMINARY ANALYSES OF VA ADMINISTRATIVE DATA
The VA Health Economics Resource Center examined national data extracts from the VA Decision Support System (DSS) to identify use of DAA medications and IL-28B testing VA for the period of July 2011 through June 2012. Administrative data were also used to identify the size of the population with HCV infection. VA cost data from the 2010 federal fiscal year were analyzed to determine the cost of care for patients with different stages of liver disease.

VA Population with Chronic HCV Receiving VHA Care
The VA hospital discharge and outpatient visit files for the year ending 9/30/2011 were used to identify all persons who received at least one service that was assigned an ICD-9 diagnosis code for HCV. For this time period, the national prevalence of an HCV ICD-9 diagnosis code is approximately 2.6%.

Prescription Data on DAA Medication Use
The VA DSS National Data Extract of prescription data was analyzed for the use of DAA medications boceprevir or telaprevir. A record was considered to refer to a DAA if all of the following were true:

- National Drug Code (NDC) was for one of these DAA medications
- Internal entry number (IEN) from the VA drug file was for one of the DAA medications
- The DSS Intermediate Product (IPNUMBER) was either for a specific DAA or for a “new drug.”

The text in the drug description field was not used to identify DAA medications. The text “telaprevir” did not appear in any record. The text “boceprevir” did not appear in the drug description field of these records until the 2012 fiscal year. An additional 169 records that had text description that included the string “boceprevir FY12”, and DSS intermediate product number for pegylated interferon, were reviewed. Records that had a quantity of medication that was consistent with boceprevir were included in the analysis.
Data on IL-2B Genotype Testing Use
The DSS National Data Extract of laboratory orders was evaluated. All records with a laboratory test description containing the text “IL-28” were included in the analysis.

VISN-level Analyses
To enable VISN-level analyses, we assigned VISN number using the VISN recorded in the first record for a DAA prescription fill in the pharmacy data, or the first IL-28B test in the laboratory data. We used the first record in order to be consistent in characterizing number of new treatments and the length of treatment episodes. When we combined the lab data (on IL-28B testing) with prescription data (on DAA fills), if the VISN was not the same in the two sources, the conflict was resolved by using the VISN in the earlier record.

Key Question #1 Analysis Plan: What are the current usage patterns of directly acting antivirals and of IL-28B patient genotyping in the VA health system? And how do these patterns differ by VISN?
We divided this overarching question into a number of related sub-questions answered individually below.

Sub-question 1.1: How many people initiated DAAs during 07/1/11-06/30/12? How did this differ across VISNs? How has this changed since the introduction of DAAs into VA?
We created a person-level file using prescription records during the year 7/1/11-6/30/12. We summarized the data so that there was one record per patient. The summary record included a patient identifier, a variable to indicate if the patient initiated boceprevir, and the month when this medication was first dispensed. Each summary record also included a variable to indicate whether telaprevir was initiated and the month that this medication was first dispensed. This patient-level file was used to determine the number of unique persons initiating DAA, and the number initiating each medication.

Sub-question 1.2: How many unique people had an IL-28B test during 07/1/11-06/30/12? How did this differ across VISNs?
We created a person-level file from qualifying IL-28B laboratory records from the study year. The file included the patient identifier and an indicator that the patient received at least one IL-28B test during the study year. We report the total number of patients who had an IL-28B test.

Sub-question 1.3: Among people receiving DAA, how many had IL-28B testing? Among those with IL-28B testing, how many received DAA therapy? How does this differ across VISNs?
We approached this question in two ways. We first compared the counts of individuals initiating DAA therapy and being tested with IL-28B testing by VISN without examining whether the counts were of the same individuals or not. Second, we combined the person-level prescription and laboratory files from the study year, and created a 2 x 2 table to show the number receiving a DAA medication, an IL-28B test, or both. Note that the cell for neither is not included, as persons had to receive either a DAA medication or an IL-28B test to be included.
Sub-question 1.4: Among persons who initiated DAA treatment during the study year, what is the length of their treatment episode?

We examined how long individuals initiating DAAs were on treatment before ending it. From the data available, we could not ascertain the reason for ending treatment (e.g., treatment success, discontinuation because of an adverse event, etc.). Our analysis considered the incomplete nature of the data available. We extracted data from 7/1/2011 until 5/31/2012. In this analysis, we excluded data from June, 2012, to be certain that results would not be affected by possible incomplete processing of prescriptions filled at the end of the study period. We had between one month and one year of prescription data on those who initiated DAA treatment in this period.

We evaluated treatment duration using a method similar to a survival analysis. We used these data to characterize the percentage of persons with available data who were still in treatment at each interval of time. We created one record for each patient for each medication, and called this a treatment episode. We found the length of treatment and the length of follow-up. We ignored any treatment gaps resulting from delays in filling prescriptions in defining the duration of treatment. We use the following procedure:

First, we excluded cases with uncertain data. Most records reported the days’ supply of medication that was dispensed. If this field was missing, we estimated the days of supply by dividing the quantity of drug by the recommended daily dose (12 pills for boceprevir or 6 pills for telaprevir). We excluded 3% of the records with a value of more than 90 days of supply dispensed at single prescription fill date.

Second, we then created an episode data base with one record for combination of person and drug (a small number of persons initiated treatment with both drugs, and when this occurred we included both starts in our data). Although data were extracted for the month of June, 2012, we excluded these data as we were uncertain if all records from that month had been processed. We created an episode database with the following variables:

- **Medication**: The medication for this episode, either boceprevir or telaprevir.
- **Total days supply**: The total day supply in all prescription fills.
- **Days of treatment**: The number of days of treatment was defined as the greater of two numbers: the total number of days’ supply of medication that was dispensed, or the number of days between the date the prescription was first dispensed and the date that the last prescription would have been exhausted. The first number, days’ supply of medication, represents the length of treatment in patients who were prompt in filling prescriptions. The second number represents the duration of treatment in patients who were not prompt in refilling prescriptions, and includes some days in which medication doses were missed.
- **Medication possession ratio**: The medication possession ratio was the total days of supply divided by the number of days from treatment initiation to exhaustion of last prescription. This number was less than 100% in patients who did not fill prescriptions on time. This number was more than 100% when prescriptions were
refilled promptly. In this case, there was an accumulated a supply of medication available to take when this last fill would otherwise have been exhausted.

- **Days of follow-up**: The days of follow-up was the number of days from treatment initiation to the end of follow-up (5/31/12), that is, the date that information about this treatment episode was censored by limits of the data extract. Episodes in which days of supply exceeded the days of follow-up are censored; there is insufficient information to know the length of that treatment episode. There is sufficient information to know that the treatment lasted at least as long as the number of days of follow-up.

- **Month in which treatment was initiated**: The month in which the first prescription was filled. We used this information to see if there was a trend in the number of individuals starting treatment.

Third, we characterized length of treatment, considering the limitation of follow-up. We considered the percentage of people who were still receiving the DAA in each 4 week interval (after 4 weeks, after 8 weeks, after 12 weeks, etc.). For each interval, we computed: 1) the denominator (number who could have been treated this long, that is, whose follow-up was not yet censored); and 2) the numerator (number actually treated this long). For example, we evaluated the episode database for boceprevir to see treatments that lasted at least 4 weeks. We counted as the denominator the number of persons still being followed, those who initiated treatment more than 28 days before the last date in the prescription data. We counted in the numerator the number of these persons (with 28 days of follow-up) who had at least 28 days of treatment. Note that it was possible for an individual to have more days of medication than days of follow-up, and that we only included in the numerator those eligible for the denominator. This analysis was repeated for subsequent 4 weeks intervals, until there were no more cases that met the criteria for the denominator (52 weeks).

**Key Question #2: What will be the health impacts of using either of two available directly acting antivirals combined with pegylated interferon and ribavirin (triple therapy)?**

The analytic plan for addressing Key Question #2 involved three steps:

1. **Synthesizing VA-specific data into model-usable inputs**: Information from administrative data analyses and literature reviews were combined to produce inputs usable by the model.

2. **Running VA-specific cohorts through the simulation model under each treatment strategy at various rates of uptake for the new DAAs**: Simulations were conducted using computers and TreeAge modeling software. Under each combination of treatment and uptake rate, the model produced a set of outputs that were then analyzed to address the Key Question.

3. **Computing multiple, annual health impacts over a 5 year horizon**: Improving treatment efficacy has the potential to ameliorate a variety of non-fatal and fatal outcomes. Non-fatal outcomes included decompensated cirrhosis, hepatocellular carcinoma, and the need for liver transplant. We considered mortality due to chronic HCV in general and to advanced liver disease in particular. We combined the effects of non-fatal and fatal outcomes into a single,
standard measure – quality-adjusted life years (QALYs). All outcomes were computed over a 5 year horizon and reflect the annualized difference between standard two-drug therapy and alternatives that included a DAA as part of HCV treatment. As the goal was to consider short-term effects within the VA Health System, results DO NOT consider lost life years or reduced quality-of-life for individuals in years after the 5 year horizon and therefore likely underestimate the full health benefits of patients’ lifetimes.

Key Question #3: How will the magnitudes of the health impacts measured in Key Question #2 change if IL-28B patient genotyping is used to offer triple therapy to those less likely to benefit from two-drug pegylated interferon + ribavirin?

The analytic plan for Key Question #3 was the same as that of Key Question #2 except that instead of evaluating universal triple therapy, the treatment strategy that was evaluated was IL-28B patient genotyping to guide who receives standard two-drug therapy and who receives triple therapy with a DAA.

Key Question #4: What will be the cost and resource use patterns when using either triple therapy or IL-28B-guided triple therapy?

The analytic plan for Key Question #4 was the same as that of Key Questions #2 and #3 except that the cost impacts over a 5 year horizon were considered. This meant that costs of treatment, contingent on response guided therapy protocols and adherence, were tallied for individuals initiating treatment. Costs depended on treatment effectiveness, as the model tallied the effect of sustained viral response in averted treatment of advanced liver disease. Like health benefits, costs were only considered for a 5 year period. The effectiveness of treatment strategies after the 5 year horizon were not considered, and therefore the estimates are likely underestimate the full lifetime cost effects and do not represent lifetime horizon needed to estimate cost-effectiveness.

The costs of inpatient and outpatient care are based on relative values of the national average Medicare reimbursement rate, adjusted to correspond to actual VA expenditures (the HERC average cost estimates). These estimates were based on an analysis of cost of care provided to VA patients with HCV who received care in the 2010 federal fiscal year conducted by the Health Economics Resource Center. Pharmacy costs were based on data in the DSS prescription-level national data extract from the same period, with the exception of cost of DAA medications. All cost estimates include both the direct costs of care and the indirect (overhead) costs of providing that care.

PEER REVIEW

A draft version of this report was reviewed by six technical experts as well as clinical leadership. Their comments and our responses are presented in Appendix A.
RESULTS USED TO INFORM THE MODEL

Table 1 below shows the number of sources with information relevant to various parts of the topic.

Table 1. Number of Sources Identified for Each Model Attribute/Area

<table>
<thead>
<tr>
<th>Attribute</th>
<th># of Sources</th>
<th>Attribute</th>
<th># of Sources</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>28</td>
<td>Treatment eligibility</td>
<td>10</td>
</tr>
<tr>
<td>Sex</td>
<td>27</td>
<td>Treatment uptake</td>
<td>9</td>
</tr>
<tr>
<td>Race/ethnicity</td>
<td>25</td>
<td>Treatment completion</td>
<td>11</td>
</tr>
<tr>
<td>Fibrosis stage</td>
<td>11</td>
<td>Treatment effectiveness</td>
<td>13</td>
</tr>
<tr>
<td>HCV genotype</td>
<td>15</td>
<td>Side-effects</td>
<td>4</td>
</tr>
<tr>
<td>Liver transplant</td>
<td>2</td>
<td>HCV care costs</td>
<td>1</td>
</tr>
<tr>
<td>Liver cancer</td>
<td>3</td>
<td>Drug costs</td>
<td>1</td>
</tr>
<tr>
<td>Mortality</td>
<td>4</td>
<td>Side-effect costs</td>
<td>1</td>
</tr>
<tr>
<td>HCV clearance</td>
<td>4</td>
<td>Advanced liver disease costs</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Quality of life</td>
<td>8</td>
</tr>
</tbody>
</table>

We now describe the information from the published studies within the sources noted in the table above. Many studies describe the demographic and health characteristics of Veterans with chronic HCV infections. The mean age of individuals with chronic HCV infections is between 45-55 years in most studies with the majority in the low to mid 50s.2-26 Most individuals with chronic HCV in VA are male, with study means falling between 90-100% with the majority at 97%.2-4,6,7,9-19,21-25,27 Race/ethnicity reports tend to be complete in smaller clinical studies with substantial portions marked as missing or unknown in very large registry and administrative studies. Even so, if one looks at the proportion of White to African American individuals among those whose race/ethnicity is reported, there is reasonable stability across studies with a ratio of between 2.0:1 and 2.5:1 being common – hence for the analysis we assume that of African American and White individuals, the percentage that were White was assumed to be 69%.2-4,6,11,13-16,18-21,23-28 HCV genotype is reported in a number of studies, though often not all individuals in the study have their HCV infection genotyped and sometimes genotypes 1 and 4 are grouped together as are genotypes 2 and 3. In these studies, typically 70-85% of chronic HCV infections are genotype 1.2,5,7,10,11,13,15,17,19,22,24-27 Liver fibrosis stage distribution is important information that is not reported in many studies, with F0-F2 often grouped together and F3-F4 grouped together. In some studies, only F4 and decompensated cirrhosis are reported. Typically the F2 and F3 fibrosis stages are the most common in these studies.6,7,10,13,17,19,24-27,29 Clearance rates of chronic HCV infection are reported in one study.20 These data inputs to the model are summarized in Table 2, below.
Table 2. Demographic Characteristics Assumed for VA HCV GT1 Population

<table>
<thead>
<tr>
<th>Model Input</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>55</td>
</tr>
<tr>
<td>Sex</td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>97%</td>
</tr>
<tr>
<td>Female</td>
<td>3%</td>
</tr>
<tr>
<td>Race</td>
<td></td>
</tr>
<tr>
<td>White</td>
<td>69%</td>
</tr>
<tr>
<td>African American</td>
<td>31%</td>
</tr>
<tr>
<td>Fibrosis Distribution (see below for alternatives)</td>
<td>8%</td>
</tr>
<tr>
<td>F0</td>
<td>25%</td>
</tr>
<tr>
<td>F1</td>
<td>33%</td>
</tr>
<tr>
<td>F2</td>
<td>20%</td>
</tr>
<tr>
<td>F3</td>
<td>14%</td>
</tr>
<tr>
<td>F4</td>
<td></td>
</tr>
</tbody>
</table>

Fewer studies provide detailed data on advanced liver disease. Few studies report data on liver transplantation, though a review of liver transplant outcomes in African Americans includes information on African American Veterans. Likewise, there is relatively little information on hepatocellular carcinoma in the chronic HCV infected Veterans. These data inputs to the model are summarized in Table 3, below.

Table 3. Transplantation for Advanced Liver Disease related to HCV

<table>
<thead>
<tr>
<th>Model Input</th>
<th>Value</th>
<th>Sources/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rate of liver transplantation for individuals with decompensated cirrhosis (chronic genotype 1 HCV who are treatment eligible) (# per 100,000 person years)</td>
<td>2,500</td>
<td>Based on preliminary analyses of VA administrative data for 2010 prepared by HERC, it appears that approximately 0.5% have liver transplants within VA itself. However, these data rely on a very small sample size and only 6 months of follow-up on average. Specifically, among 16,234 VA patients with cirrhosis in FY10, 79 (.49%) had a liver transplant during the year. This count includes transplants provided by non-VA providers if these were sponsored by VA. Given that the model tracks post-transplant care within VA even if transplants themselves occur outside VA, we assume a higher rate so as not to undercount costs in the model.</td>
</tr>
</tbody>
</table>
A number of studies provide information on HCV treatment-related parameters within VA. Consistent information on the proportion of Veterans who are treatment eligible is less available as the definition of treatment eligibility differs between studies and between clinician assessment as well as official VA guidance over time in this regard. In general, treatment eligibility ranges from approximately 30-55% and is most commonly in the 40-45% range, though this may be somewhat lower in the VA population if the studies were conducted in populations who are more likely to be eligible for treatment. Studies on treatment uptake also are less straightforward to compare as some report uptake among those who are treatment eligible and some report on uptake among all participants. Furthermore, uptake is often reported as a cumulative percentage with different lengths of follow-up. Long-term uptake among treatment eligible individuals ranges from approximately 20-50% in studies with 30-35% being the most common. For similar reasons, treatment completion rates reported in various studies are difficult to compare, as are treatment success rates. Given these challenges, we describe how we estimate treatment completion and success rates for the VA population we model below.

HCV treatment completion and success rate information for the VA population, especially for very recently introduced triple therapy that includes a DAA, is not readily available. We estimated these parameters using the following methods for both standard two-drug treatment and triple therapy. For both standard treatment and triple therapy, we used the race/ethnicity distributions derived as described in the preceding paragraphs. Because, treatment effectiveness was predicated on IL-28B genotype, we used the distribution of CC versus non-CC (CT and TT) IL-28B genotypes by race/ethnicity reported in Thompson (2010).

For standard two-drug treatment, overall rates of treatment completion were similar across multiple studies within VA. Because the data from Beste (2010) provides information on which individuals quit due to treatment failure versus an unspecified reason, we used this study in particular to estimate the overall rate of treatment non-completion for a reason other than treatment failure. Butt (2010) showed that African Americans were 10% less likely to complete treatment than individuals of other races, so we calculated race-specific treatment non-completion rates. Beste (2010) also identified the overall proportion of patients who terminated
treatment due to treatment failure at 12 and 24 weeks.\textsuperscript{33} We estimated the race- and IL-28B-genotype stratified relative risks of treatment failure at 12 and 24 weeks based on Thompson (2010).\textsuperscript{34} Using these new race- and IL-28B genotype-stratified probabilities of treatment failure at 12 and 24 weeks, we computed the race- and IL-28B genotype stratified rates of SVR for patients who completed 48 weeks of treatment such that these SVR rates satisfied race-specific SVR rate ratios for CC to non-CC types (Thompson 2010) and the overall intent to treat SVR rate observed in Kramer (2012) (i.e., 27% in non-African Americans and 15.8% in African Americans).\textsuperscript{15} These data inputs to the model are summarized in Table 4, below.

For triple therapy, we used a very similar process to that for standard two-drug therapy. Importantly, no studies report on treatment completion rates for triple therapy in VA since these treatments have only recently been introduced. The assumptions we used, therefore, were less VA-specific than for standard two-drug therapy and more closely resembled our previously published analysis.\textsuperscript{1} We assumed that patients do not complete treatment for reasons other than treatment failure at the same rate whether they are receiving standard or triple therapy, using standard therapy VA-specific discontinuation rates described above. We assumed that the race- and IL-28B-genotype specific 12 week treatment failure rate was the same for patients receiving standard or triple therapy, also as described above. These small changes in assumptions, while maintaining all of other assumptions from the prior analysis,\textsuperscript{1} resulted in triple therapy intent to treat SVR rates of 48.9% in non-African Americans and 37.3% in African Americans. These data inputs to the model are summarized in Table 4, below.

Table 4. Treatment Parameters Estimates for the VA HCV GT1 Population

<table>
<thead>
<tr>
<th>Model Input</th>
<th>Value for Whites</th>
<th>Value for African Americans</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treatment dropout rate (# per 100,000 person years)</td>
<td>37,040</td>
<td>48,534</td>
</tr>
<tr>
<td>Standard Two-Drug Therapy Parameters</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Early Virologic Response (EVR) at 12 weeks</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CC genotype</td>
<td>98%</td>
<td>97%</td>
</tr>
<tr>
<td>Non-CC genotype</td>
<td>91%</td>
<td>86%</td>
</tr>
<tr>
<td>Continue treatment beyond 24 weeks (conditional on EVR at 12 weeks)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CC genotype</td>
<td>97%</td>
<td>89%</td>
</tr>
<tr>
<td>Non-CC genotype</td>
<td>86%</td>
<td>82%</td>
</tr>
<tr>
<td>Sustained Virologic Response (SVR) (conditional on 48 weeks of treatment)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CC genotype</td>
<td>60%</td>
<td>60%</td>
</tr>
<tr>
<td>Non-CC genotype</td>
<td>34%</td>
<td>27%</td>
</tr>
<tr>
<td>Triple Therapy Parameters</td>
<td></td>
<td></td>
</tr>
<tr>
<td>No virologic failure at 12 weeks</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CC genotype</td>
<td>98%</td>
<td>97%</td>
</tr>
<tr>
<td>Non-CC genotype</td>
<td>91%</td>
<td>86%</td>
</tr>
</tbody>
</table>
### Model Input

<table>
<thead>
<tr>
<th>Model Input</th>
<th>Value for Whites</th>
<th>Value for African Americans</th>
</tr>
</thead>
<tbody>
<tr>
<td>No virologic failure at 24 weeks (conditional on no failure at 12 weeks)</td>
<td>62%</td>
<td>48%</td>
</tr>
<tr>
<td>CC genotype</td>
<td>43%</td>
<td>48%</td>
</tr>
<tr>
<td>Non-CC genotype</td>
<td></td>
<td></td>
</tr>
<tr>
<td>No virologic failure at 48 weeks (conditional on no failure at 12 weeks)</td>
<td>28%</td>
<td>38%</td>
</tr>
<tr>
<td>CC genotype</td>
<td>42%</td>
<td>38%</td>
</tr>
<tr>
<td>Non-CC genotype</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sustained virologic response given 24 weeks of treatment</td>
<td>98%</td>
<td>95%</td>
</tr>
<tr>
<td>CC genotype</td>
<td>95%</td>
<td>89%</td>
</tr>
<tr>
<td>Non-CC genotype</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sustained virologic response given 48 weeks of treatment</td>
<td>75%</td>
<td>70%</td>
</tr>
<tr>
<td>CC genotype</td>
<td>65%</td>
<td>60%</td>
</tr>
<tr>
<td>Non-CC genotype</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

A number of studies report quality-of-life for Veterans with chronic HCV infections both for those not on treatment as well as those while on treatment (including rates of side-effects).\(^{19,21,22,27,28,35–40}\)

Notably, very limited information appears in the published literature on the cost of HCV treatment and care for Veterans in VA. For costs we relied on prior communications with the Office of Pharmacy Benefits Management as well as preliminary analyses performed by HERC. Additionally, both for costs and other information, we relied on the VA State of Care report on HCV.\(^1\) The cost data included in the model are summarized in Table 5, below.

### Table 5. VA-specific Cost Inputs

<table>
<thead>
<tr>
<th>Cost Type</th>
<th>Amount</th>
<th>Sources/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cost of Peg-RIB 48 weeks and care/monitoring during that time(^*)</td>
<td>$15,281</td>
<td>Peg-RIB costs $9,120 to which we add costs of care during the 48 weeks of treatment of $6,161</td>
</tr>
<tr>
<td></td>
<td></td>
<td>(assuming a full 48 weeks) assumed to be 1.5 times the costs of HCV care prior to treatment success to</td>
</tr>
<tr>
<td></td>
<td></td>
<td>account for other monitoring, etc.</td>
</tr>
<tr>
<td>Additional Cost of Boceprevir (24 weeks) (to be added to the</td>
<td>$18,753</td>
<td>Assumed Boceprevir (provisional) FSS price is $3,125.49 per 28 day supply</td>
</tr>
<tr>
<td>Cost of Peg-RIB 48 weeks above)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Additional Cost of Telaprevir (12 weeks) (to be added to the</td>
<td>$36,828</td>
<td>Assumed Telaprevir (provisional) FSS price is $12,276.10 per 28 day supply</td>
</tr>
<tr>
<td>Cost of Peg-RIB 48 weeks above)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Average adverse events costs 2 drug therapy</td>
<td>$1,920</td>
<td></td>
</tr>
<tr>
<td>Cost Type</td>
<td>Amount</td>
<td>Sources/Notes</td>
</tr>
<tr>
<td>----------------------------------------------------</td>
<td>---------</td>
<td>------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Average adverse events costs 3 drug therapies</td>
<td>$2,586</td>
<td>The mix of adverse events is different for Boceprevir and Telaprevir but the average costs (likelihood times cost of dealing with the side-effects, summed over all side-effects) for both drugs have been observed to be quite similar (see for example, Stephens, et. al. AASLD poster, 38).</td>
</tr>
<tr>
<td>Annual HCV care (w/o Peg-RIB or other treatment costs)</td>
<td>$4,450</td>
<td>HERC preliminary analysis of 2010 data: Since this is just care that is related to HCV and liver disease we take the difference of the total cost of care for people with uncomplicated chronic HCV ($11,486) and subtract the average cost of care for people in VA ($7,036)</td>
</tr>
<tr>
<td>Annual post-successful treatment HCV care costs</td>
<td>$2,225</td>
<td>HERC preliminary analysis of 2010 data, per note above: We assume that this care is roughly 50% of the cost of care prior to achieving treatment success as seen in studies not specific to VA HCV patient populations.</td>
</tr>
<tr>
<td>Annual decompensated cirrhosis care costs (w/o Peg-RIB or other Tx)</td>
<td>$13,093</td>
<td>HERC preliminary analysis of 2010 data, per note above: We subtract from the costs for those with decompensated cirrhosis ($20,129) the average costs of care for people in VA ($7,036).</td>
</tr>
<tr>
<td>Annual HCC costs (w/o Peg-RIB or other Tx)</td>
<td>$71,954</td>
<td>HERC preliminary analysis of 2010 data suggests an annual cost of $33,096 among all individuals, including those who died and did not complete full year of treatment. Since our cost is conditional on survival (model cycle length much shorter than 1 year), we used a VA report and other data that suggest a roughly 15% 3-year survival. (<a href="http://www.hepatitis.va.gov/provider/reviews/HCC.asp">http://www.hepatitis.va.gov/provider/reviews/HCC.asp</a> and Surveillance, Epidemiology and End Results (SEER)) which implies that the cost should be multiplied by [1.00/0.46], implying the cost of $71,954.</td>
</tr>
<tr>
<td>Year of Liver Transplant cost of care</td>
<td>$152,313</td>
<td>HERC preliminary analysis of 2010 data, adjusted for censoring of people who die and do not complete full year of treatment: $134,036 (using 1.00/0.88 again as the survival multiplier as above) Other sources suggest that costs are closer to: $250,000 but may include the transplant itself as well as a 7-day hospital stay. Still other sources suggest $150,000 - $250,000 range (<a href="http://www.hepatitis.va.gov/pdf/feedback-forum.pdf">http://www.hepatitis.va.gov/pdf/feedback-forum.pdf</a> from 2007)</td>
</tr>
</tbody>
</table>
Assessment of Alternative Treatment Strategies for Chronic Genotype 1 Hepatitis C
Evidence-based Synthesis Program

<table>
<thead>
<tr>
<th>Cost Type</th>
<th>Amount</th>
<th>Sources/Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Years post Liver Transplant</td>
<td>$32,903</td>
<td>HERC preliminary analysis of 2010 data, adjusted for censoring of people who die and do not complete full year of treatment: $31,587 (here we use a 1.00/0.96 survival multiplier) Other sources suggest $12,000 as the annual medication cost alone (<a href="http://www.hepatitis.va.gov/patient/complications/transplant-basics.asp">http://www.hepatitis.va.gov/patient/complications/transplant-basics.asp</a>)</td>
</tr>
</tbody>
</table>

* Note: For the costs of treatment using response guided algorithms (i.e., triple therapies), costs are scaled for early stopping due to Early Virologic Response or failure to achieve sufficient reductions per response guided therapy in the model itself.

We defined a representative cohort of chronic HCV GT1 infected individuals in VA based on published studies of VA HCV populations and other VA-specific documents and data which are described in the results. The cohort’s age is 55 years with 97% male, 69% white, and 31% African American. These characteristics as well as the liver fibrosis distribution assumed are shown in Table 2 above.

**Treatment-eligible Patient Population**

The total population of chronic HCV infected Veterans is approximately 189,065 according to the VA’s State of Care 2010 report. The report also notes that this number has stayed stable over the preceding 5 years. Of these, based on the literature review, we assume that approximately 80% are genotype 1 HCV infections – the major genotype with the lowest overall response rate to standard two-drug therapy, for which DAAs appear to offer the greatest benefit, and in which they have been best studied to date. Of these individuals, again based on the literature review, approximately 45% are treatment-eligible. Finally, since the analysis focuses on treatment-naïve individuals and based on the State of Care 2010 report as well as the published literature, we assume that approximately 70% of individuals have not been treated previously.

\[8,000 = 189,065 \times 0.80 \times 0.45 \times 0.70\]

Based on these calculations, the analysis uses an estimate of approximately 48,000 GT1 chronic HCV-infected, treatment-eligible, treatment-naïve Veterans for determining total costs and health benefits.

**Uptake Scenarios**

The analysis considered multiple uptake scenarios. In all scenarios, the comparator was standard two-drug therapy offered to all treatment-eligible patients with the assumption that 2% of this group took up therapy annually over the 5 year window considered in the analysis. Uptake scenarios considered the effects of DAAs possibly combined with IL-28B genotyping at three different levels of uptake:

- Approximately 2% of treatment-eligible chronic HCV GT1 infected Veterans take-up HCV treatment each year, similar to uptake rates for standard two-drug therapy
Approximately 4% each year, double the uptake rates for standard two-drug therapy – slightly above those actually observed in VA towards the latter half of FY2008, based on the preliminary analyses reported below (Figure 2).

Approximately 8% each year, quadruple the uptake rates for standard two-drug therapy

Multiple uptake scenarios were explored because future uptake is highly uncertain. There is little experience with DAAs and IL-28B genotyping as they have only recently become available in VA. The effect of newer treatments and technologies currently in clinical testing contributes to this uncertainty. Figure 2 below compares historical rates of uptake of standard two drug therapy to the uptake scenarios we consider for DAA strategies.

Figure 2. Cumulative Proportion of Treatment-eligible, Chronic HCV Individuals Taking Up Therapy

Combining Uptake Scenarios with the Treatment-eligible Population for Analyses

Table 6 estimates the number of individuals initiating treatment under each uptake scenario. The analyses consider what would happen over the next five years if the strategy was switched from standard two-drug therapy to each of the two other alternatives. Separate estimates are made for each strategy under each of the three uptake scenarios.

Table 6. Treatment Eligibility and Uptake over 5 Years (number of Veterans)

<table>
<thead>
<tr>
<th>Category</th>
<th>Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Veterans with HCV</td>
<td>189,065</td>
</tr>
<tr>
<td>Veterans with GT1 HCV</td>
<td>106,667</td>
</tr>
<tr>
<td>Veterans with GT1 HCV eligible for treatment</td>
<td>48,000</td>
</tr>
<tr>
<td>Current uptake rate (2%/year)</td>
<td>15,495</td>
</tr>
<tr>
<td>Doubled uptake rate (4%/year)</td>
<td>26,702</td>
</tr>
<tr>
<td>Quadrupled update rate (8%/year)</td>
<td>36,609</td>
</tr>
</tbody>
</table>
KEY QUESTION #1. What are the current usage patterns of directly acting antivirals and of IL-28B patient genotyping in the VA health system? And how do these patterns differ by VISN?

Sub-question 1.1: How many people initiated DAAs during 07/1/11-06/30/12? How did this differ across VISNs? How has this changed since the introduction of DAAs into VA?

Between July 2011 and June 2012 nearly 3,000 people initiated DAA treatment, with approximately 80% using on-formulary boceprevir (Boceprevir N=2,366, Telaprevir N=501). There was heterogeneity in the number of people taking up DAA therapies across VISNs (see Figure 3). Part of this difference must be attributed to differences in the number of treatment-eligible chronic HCV-infected Veterans in each VISN. Uptake of DAAs increased since July 2011, but seems to have stabilized at approximately 300 new people initiating DAAs per month. If the uptake pattern of approximately 300 per month continues over the next year, this would imply that approximately 3,000-4,000 new DAA treatments might be expected to be initiated annually, assuming January 2012 through May 2012 indicate longer-term average usage in VA of DAAs. This uptake rate is then slightly higher than the 3,393 standard two-drug (PEG-RIB) treatments initiated in 2008, as the State of Care 2010 report states. It is however unclear if this uptake rate will continue in subsequent years (backlog vs. popularization vs. waiting for even newer drugs).

Figure 3. Uptake of DAA Therapies by VISN (x-axis denotes VISN number)
Sub-question 1.2: How many unique people had an IL-28B test during 07/1/11-06/30/12? How did this differ across VISNs?

During the period of interest, 2,171 individuals had an IL-28B test. Currently VA IL-28B tests are send-outs. There was heterogeneity in use of IL-28B testing across VISNs. Only part of this variation is explained by differences in the number of treatment-eligible chronic HCV-infected Veterans in each VISN. Use of IL-28B testing across VISNs is represented in light shading in Figure 4, below.

Sub-question 1.3: Among people receiving DAA, how many had IL-28B testing? Among those with IL-28B testing, how many received DAA therapy? How does this differ across VISNs?

Figure 4. Use of IL-28B Testing and DAAs by VISN

IL-28B testing is used for those not receiving DAAs, and DAAs are generally used without IL-28B genotyping. Only 306 patients used both, whereas 2,551 patients only used DAAs, and 1,865 patients only used IL-28B testing. VISNs differ on the rates of use of IL-28B testing in patients who received DAAs, with a national average just above 10 percent. VISN 22 had the greatest number of IL-28B tests, while VISNs 8, 16, and 21 had the greatest number of patients initiating DAA therapy. In some VISNs there were more patients initiating DAA therapy than getting IL-28B tests, while in other VISNs it was the reverse. Seven VISNs used testing in five percent or less of patients receiving DAA, whereas three VISNs used testing on 30 percent or more of these patients.

Using DAAs without information on a patient’s IL-28B genotype was common in many VA care settings, although there was diversity of practice. The reasons for these differences remain to be explored. They may include other uses of the IL-28B information, such as trying to understand why a patient failed to achieve sustained virologic response to a previous treatment. Tests may be more common in some settings because they are easier to order, because some subgroups of providers are more familiar with their use, or because they are more appropriate in some patient subgroups.
Sub-question 1.4: Among persons who initiated DAA treatment during the study year, what is the length of their treatment episode?

The median length of boceprevir treatments was just under 28 weeks (see Figure 5). Of those who initiated boceprevir, 89% got to 8 weeks, 81% to 12 weeks, 76% to 16 weeks, and 29% to 32 weeks. Telaprevir episodes were much shorter per its therapeutic protocol. Median length of telaprevir treatments was between 12 and 16 weeks. None lasted beyond 28 weeks.

The medication possession ratio indicated that most patients were highly adherent and that those who continued in treatment filled prescriptions promptly.

Figure 5. The Days on Treatment for Each DAA Appear Reasonably in Line with Its Therapeutic Protocols

KEY QUESTION #2. What will be the health impacts of using either of two available directly acting antivirals combined with pegylated interferon and ribavirin (triple therapy)?

With our model, we compared universal triple therapy to standard two-drug therapy over a five year analysis period for eligible GT1 HCV patients (N=48,000) (see Table 7). This comparison was made for three potential uptake rates: the current uptake rate (two percent per year), a doubled uptake rate (four percent per year), and a quadrupled uptake rate (eight percent per year). When compared to standard therapy, universal triple therapy was likely to reduce annual cases of decompensated cirrhosis by 10-29 (current uptake: 10; doubled uptake: 29; quadrupled uptake: 50). When comparing universal triple therapy to standard therapy, annual cases of hepatocellular carcinoma were likely to be reduced by 5-16 (current: 5; doubled: 16; quadrupled: 27). Finally, when comparing universal triple therapy to standard therapy, annual numbers of liver transplants are likely to be reduced by 0-1 (current: 0; doubled: 1; quadrupled: 2). Consequently, annual quality adjusted life years (QALYs) increased by 148-213 (current: 148; doubled: 213; quadrupled: 322).
Table 7. Annual Effect of Universal Triple Therapy on Health Outcomes over 5 Years

<table>
<thead>
<tr>
<th></th>
<th>Current Uptake Rate (2%/yr)</th>
<th>2x Uptake Rate (4%/yr)</th>
<th>4x Uptake Rate (8%/yr)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cases of Decompensated Cirrhosis</td>
<td>-10</td>
<td>-29</td>
<td>-50</td>
</tr>
<tr>
<td>Cases of Hepatocellular Carcinoma</td>
<td>-5</td>
<td>-16</td>
<td>-27</td>
</tr>
<tr>
<td>Number of Liver Transplants</td>
<td>0</td>
<td>-1</td>
<td>-2</td>
</tr>
<tr>
<td>Quality Adjusted Life Years</td>
<td>+148</td>
<td>+213</td>
<td>+322</td>
</tr>
</tbody>
</table>

N=48,000 eligible GT1 HCV

**KEY QUESTION #3. How will the magnitudes of the health impacts measured in Key Question #2 change if IL-28B patient genotyping is used to offer triple therapy to those less likely to benefit from two-drug pegylated interferon + ribavirin?**

Using our model, we also compared IL-28B-guided therapy to standard two-drug therapy over a five year analysis period for eligible GT1 HCV patients (N=48,000) (see Table 8). This comparison was made for the same three potential uptake rates: the current uptake rate (two percent per year), a doubled uptake rate (four percent per year), and a quadrupled uptake rate (eight percent per year). In these comparisons, annual cases of decompensated cirrhosis are likely to be reduced by 8-26 (current uptake: 8; doubled uptake: 26; quadrupled uptake: 45), annual cases of hepatocellular carcinoma are likely to be reduced by 4-14 (current: 4; doubled: 14; quadrupled: 25), and annual numbers of liver transplants are likely to be reduced by 0-1 (current: 0; doubled: 1; quadrupled: 2). Consequently, annual QALYs increased by 110-145 (current: 110; doubled: 145; quadrupled: 225).

Table 8. Annual Effect of IL-28 Guided Triple Therapy on Health Outcomes over 5 Years

<table>
<thead>
<tr>
<th></th>
<th>Current Uptake Rate (2%/yr)</th>
<th>2x Uptake Rate (4%/yr)</th>
<th>4x Uptake Rate (8%/yr)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cases of Decompensated Cirrhosis</td>
<td>-8</td>
<td>-26</td>
<td>-45</td>
</tr>
<tr>
<td>Cases of Hepatocellular Carcinoma</td>
<td>-4</td>
<td>-14</td>
<td>-25</td>
</tr>
<tr>
<td>Number of Liver Transplants</td>
<td>0</td>
<td>-1</td>
<td>-2</td>
</tr>
<tr>
<td>Quality Adjusted Life Years</td>
<td>+110</td>
<td>+145</td>
<td>+225</td>
</tr>
</tbody>
</table>

N=48,000 eligible GT1 HCV
KEY QUESTION #4. What will be the cost and resource use patterns when using either triple therapy or IL-28B-guided triple therapy?

Depending on uptake patterns, increased total expenditures for HCV treatment and care for individuals with GT1 HCV relative to standard two-drug therapy will likely be $32-$100 million annually. Table 9 below shows the details about these annual net expenditures vary depending on strategy and scenario.

Table 9. Average Annual Net Increase in Cost by Treatment Strategy and Uptake Rate over the 5 Years of the Analysis Relative to Standard Therapy

<table>
<thead>
<tr>
<th></th>
<th>Current Uptake Rate (2%/yr)</th>
<th>2x Uptake Rate (4%/yr)</th>
<th>4x Uptake Rate (8%/yr)</th>
</tr>
</thead>
<tbody>
<tr>
<td>IL-28B-guided therapy</td>
<td>$32M</td>
<td>$76M</td>
<td>$115M</td>
</tr>
<tr>
<td>Universal triple therapy</td>
<td>$43M</td>
<td>$96M</td>
<td>$144M</td>
</tr>
</tbody>
</table>

N=48,000 eligible GT1 HCV

The table gives the additional cost of each treatment strategy compared to standard two-drug therapy. The costs include the direct cost of the new medications, the cost of treating side effects, as well as averted costs of advanced liver disease and lower care costs after achieving sustained virologic response. Importantly, average annual net costs, health outcomes and quality-of-life presented in these analyses should not be used for cost-effectiveness calculations as averted costs and downstream health benefits past year 5 are not counted in the 5-year projection of the effect on health care cost.
SUMMARY AND DISCUSSION

SUMMARY OF EVIDENCE BY KEY QUESTION

Key Question #1: What are the current usage patterns of directly acting antivirals and of IL-28B patient genotyping in the VA health system? And how do these patterns differ by VISN?

Between July 2011 and the end of June 2012, nearly 3,000 people initiated DAA treatment, with approximately 80% using on-formulary boceprevir (Boceprevir N=2,366, Telaprevir N=501). During this same period, 2,171 individuals had an IL-28B test. There was heterogeneity in number of people taking up DAA therapies and IL-28B testing across VISNs.

VISNs differed in the rates of use of IL-28B testing in patients who were prescribed DAA medications, with a national average just above 10 percent. VISN 22 had the greatest number of IL-28B tests, while VISNs 8, 16, and 21 had the greatest number of patients initiating DAA therapy. In some VISNs there were more patients initiating DAA therapy than getting IL-28B tests, while in other VISNs the reverse was true. Seven VISNs used testing in five percent or less of patients receiving DAA, whereas three VISNs used testing on 30 percent or more of these patients.

The median length of boceprevir treatments was just under 28 weeks. Of those who initiated boceprevir, 89% got to 8 weeks, 81% to 12 weeks, 76% to 16 weeks, and 29% to 32 weeks. Telaprevir episodes were much shorter per its therapeutic protocol. Median length of telaprevir treatments was between 12 and 16 weeks. None lasted beyond 28 weeks.

Key Question #2: What will be the health impacts of using either of two available directly acting antivirals combined with pegylated interferon and ribavirin (triple therapy)?

When compared to standard therapy, universal triple therapy was likely to reduce annual cases of decompensated cirrhosis by 10-29 (current uptake: 10; doubled uptake: 29; quadrupled uptake: 50). When comparing universal triple therapy to standard therapy, annual cases of hepatocellular carcinoma were likely to be reduced by 5-16 (current: 5; doubled: 16; quadrupled: 27). Finally, when comparing universal triple therapy to standard therapy, annual numbers of liver transplants are likely to be reduced by 0-1 (current: 0; doubled: 1; quadrupled: 2). Consequently, annual quality adjusted life years (QALYs) increased by 148-213 (current: 148; doubled: 213; quadrupled: 322).

Key Question #3: How will the magnitudes of the health impacts measured in Key Question #2 change if IL-28B patient genotyping is used to offer triple therapy to those less likely to benefit from two-drug pegylated interferon + ribavirin?

Comparing IL-28B guided therapy to standard two-drug therapy, annual cases of decompensated cirrhosis are likely to be reduced by 8-26 (current uptake: 8; doubled uptake: 26; quadrupled uptake: 45), annual cases of hepatocellular carcinoma are likely to be reduced by 4-14 (current:
The modeling analysis focused on VA as a whole. It is clear from the preliminary VA administrative data analyses that there is heterogeneity in the adoption of DAAs and IL-28B between VISNs. We had insufficient information to project potential differences in uptake in these treatments by VISN. Furthermore, there are other patient, provider, and facility characteristics that may play a role in determining use of these new technologies and additionally, depending on the results from IL-28B testing may also play a role in determining subsequent clinical actions and patient behaviors. Information in this area could help to further refine the analyses presented here.

The modeling analysis is confined to treatment-naïve, HCV mono-infected individuals as evidence of effectiveness for those co-infected with HIV is only beginning to emerge and utilization data needed to support VA-specific analyses stratified by co-infection status are also needed. Analyses like those presented here for individuals with previous experience of HCV treatment would be important to conduct, though are complicated by a number of issues including fewer data on effectiveness, various types of treatment failures, and reasons for failure including lack of adherence to medication regimen versus non-response to appropriately taken medications.

The modeling analysis considers three strategies including one strategy where IL-28B genotyping is used to determine triple therapy treatment versus standard therapy treatment. IL-28B genotype
along with other predictive markers for treatment response are an exciting new avenue. Our analysis considers one such approach, though others may also be possible. Ultimately, all such approaches attempt to optimize over treatment response, side-effects, and costs in achieving best outcomes for individual patients.

More generally, it is unclear how uptake rates may change beyond those observed in the first year of VA administrative data. Newer therapies and technologies are in clinical trials and could potentially represent even more attractive options for clinicians and Veterans, and may supplant the treatments we considered. Conversely physician education or other diffusion of information processes could increase uptake rates over time. Uncertainties in uptake scenarios can be reduced by periodically reevaluating the VA administrative data.

**RECOMMENDATIONS FOR FUTURE RESEARCH**

Therapy for HCV is evolving rapidly and important questions remain unanswered. As clinicians use currently approved DAAs more extensively and additional DAAs become available, future research should evaluate the health and economic outcomes that result from use of these therapies. This research should evaluate: practice patterns, including variations in care among VISNs; patient selection for treatment; effectiveness of DAAs in Veterans (in contrast to efficacy as measured in randomized trials) and in specific Veteran populations, such as patients with substance use disorders; utilization and costs from treatment and complications of HCV infection (e.g., costs); impact on specific VA budgets (pharmacy care, specialty care); cost-effectiveness of treatment and genetic testing; and barriers to diffusion of high-value therapies.

**CONCLUSIONS**

Approximately 3,000 Veterans initiated care with DAAs since their approval, with about 80% receiving boceprevir. Uptake of DAAs and use of IL-28B testing varies substantially among VISNs, unadjusted for the number of patients who are eligible for treatment. Our model-based analyses indicate that use of triple therapy results in better outcomes than standard therapy, but at increased costs. Use of IL-28B to select patients for triple therapy results in modest reductions in anticipated health benefits and costs. Assessment of the cost effectiveness of use of IL-28B guided therapy or universal therapy with DAAs will require projection of long-term health outcomes and costs.
REFERENCES


44. Pearlman B, Ehleben C. Hepatitis C virus genotype 1 infection with low viral load and rapid virological response to peginterferon and ribavirin can be treated without a protease inhibitor, irrespective of IL-28B status or patient ethnicity. *Hepatology* 2012; 56 (4, suppl): 268A.